IGC Pharma Inc
For the period ended Mar 31, 2024. Filed Jun 24, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Jun 24, 2024
IGC$0.20+2.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except share data)
| March 31, 2024 ($) | March 31, 2023 ($) | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | 1,198 | 3,196 |
| Accounts receivable, net | 39 | 107 |
| Short term investments | - | 154 |
| Inventory | 1,540 | 2,651 |
| Asset held for sale | 720 | - |
| Deposits and advances | 208 | 358 |
| Total current assets | 3,705 | 6,466 |
| Non-current assets: | ||
| Intangible assets, net | 1,616 | 1,170 |
| Property, plant and equipment, net | 3,695 | 8,213 |
| Claims and advances | 688 | 1,003 |
| Operating lease asset | 198 | 326 |
| Total non-current assets | 6,197 | 10,712 |
| Total assets | 9,902 | 17,178 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | 773 | 530 |
| Accrued liabilities and others | 1,567 | 1,368 |
| Total current liabilities | 2,340 | 1,898 |
| Non-current liabilities: | ||
| Long-term loans | 137 | 141 |
| Other liabilities | 20 | 21 |
| Operating lease liability | 84 | 207 |
| Total non-current liabilities | 241 | 369 |
| Total liabilities | 2,581 | 2,267 |
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value: authorized 1,000,000 shares, no shares issued or outstanding as of March 31, 2024, or March 31, 2023. | ||
| Common stock and additional paid-in capital, $0.0001 par value: 150,000,000 shares authorized; 66,691,195 and 53,077,436 shares issued and outstanding as of March 31, 2024, and March 31, 2023, respectively. | 124,409 | 118,965 |
| Accumulated other comprehensive loss | (3,423) | (3,389) |
| Accumulated deficit | (113,665) | (100,665) |
| Total stockholders’ equity | 7,321 | 14,911 |
| Total liabilities and stockholders’ equity | 9,902 | 17,178 |
The accompanying notes should be read in connection with these consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.